Dual targeting, a new strategy for novel PARP inhibitor discovery
Author:
Affiliation:
1. Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Publisher
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine
Link
https://www.jstage.jst.go.jp/article/ddt/15/6/15_2021.01100/_pdf
Reference77 articles.
1. 1. Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH. An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J Med Chem. 2016; 59:9575-9598.
2. 2. Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med. 2006; 7:165-172.
3. 3. Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020; 19:711-736.
4. 4. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, Rodriguez MI, Linares JL, de Almodovar MR, Oliver FJ. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med. 2009; 47:13-26.
5. 5. Shen H, Ge Y, Wang J, Li H, Xu Y, Zhu Q. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors. Bioorg Med Chem Lett. 2021; 47:128169.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An update on small molecule compounds targeting synthetic lethality for cancer therapy;European Journal of Medicinal Chemistry;2024-11
2. Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro;Bioorganic Chemistry;2024-07
3. Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities;European Journal of Medicinal Chemistry;2023-11
4. Discovery of novel 2,3,4,5-tetrahydrospiro[benzo[c]azepine-1,1’-cyclohexan]-5-ol derivatives as PARP-1 inhibitors;BMC Chemistry;2023-10-27
5. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy;Pharmacological Research;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3